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Abstract The receptor tyrosine kinase tie-1 is essential for
angiogenesis where it appears to have a role in vessel maturation.
Here we have examined the effects of hypoxia and vascular
endothelial growth factor (VEGF) on the level of tie-1 protein
expressed in bovine aortic endothelial cells. Both hypoxia (2%
O2) and VEGF were found to increase tie-1 in a time-dependent
manner. Hypoxic induction was direct and effects of hypoxia and
VEGF were not additive. Experiments with actinomycin D
indicate that these activators regulate tie-1 at the transcriptional
level.
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1. Introduction
The tie family of receptors consist of two members, tie-1
and tie-2 or tek [1]. Tie-1 is a transmembrane glycoprotein of
approximately 120 kDa comprising an extracellular domain of
two immunoglobulin-like repeats separated by three EGF-ho-
mology domains and followed by three ¢bronectin III-like
repeats [2]. The intracellular portion of tie-1 contains a tyro-
sine kinase domain with a kinase insert sequence. Tie-2 shares
the same structural features as tie-1 and has an overall iden-
tity of 44% at the amino acid level, 76% identity in the intra-
cellular domain [3,4]. Two ligands, angiopoietin-1 and -2,
have recently been identi¢ed for tie-2 [5,6]. Angiopoietin-2 is
antagonistic to angiopoietin-1, preventing binding of the acti-
vating ligand and blocking its ability to stimulate tie-2 kinase
activity and autophosphorylation. Angiopoietin-1 and -2 do
not bind tie-1 and ligands for this receptor await identi¢ca-
tion. Tie-1 is expressed predominantly on vascular endothelial
cells and some haematopoietic cells [3] and is essential for
vascular development [7]. Targeted disruption of the tie-1
gene by mutagenesis in mice results in a lethal phenotype.
Mice de¢cient in tie-1 die between midgestation and around
the time of birth and exhibit extensive haemorrhage and oe-
dema [7,8]. This appears to result from a lack of endothelial
cell integrity and hyperpermeability of blood vessels, particu-
larly smaller vessels. These data are consistent with a critical
role for tie-1 in the later stages of angiogenesis promoting
vessel maturation.
Physiological control of vessel formation requires the co-
ordinated expression of angiogenic ligands and receptors at
appropriate times in the developmental programme. In addi-
tion to the tie family, members of the family of vascular
endothelial growth factor (VEGF) receptors are essential for
normal vascular development [1]. The VEGF receptor family
members VEGF-receptor-1 (VEGFR-1), also called Flt-1, and
in VEGF receptor-2 (VEGFR-2), also called Flk-1 in mice
and KDR in humans, are critical in initiating the angiogenic
process [9]. Expression of VEGFR-2 precedes tie and is seen
in angioblasts at E7.0 [10]. Tie-1 expression is ¢rst evident at
embryonic day 8.5 in angioblasts of the head, endothelium of
the dorsal aortae and yolk sac blood islands in the developing
mouse [10]. Although tie-1 is present in adult endothelium its
expression is generally increased in developing capillaries
[10,11]. Tie-1 expression is increased in endothelial cells in-
volved in angiogenesis during wound healing and tumour vas-
cularisation [12,13]. Despite the importance of this receptor,
the factors which control its expression are not known. Neo-
vascularisation is recognised to occur in situations of tissue
hypoxia, for example within growing tumours and ischaemic
tissues [14]. In this study we have tested the hypothesis that
hypoxia and VEGF control expression of tie-1 protein. We
demonstrate upregulation of tie-1 by both hypoxia and VEGF
through a transcription-dependent mechanism. These data
suggest that hypoxia and VEGF could be responsible for in-
creased expression of tie-1 seen in vessel formation during
development and under pathological conditions. These stimuli
thus act to prime the newly developed vessels for later stages
of vessel maturation.
2. Materials and methods
2.1. Materials
An a⁄nity-puri¢ed polyclonal antibody raised against a peptide
corresponding to amino acids 1121^1138 of human tie was obtained
from Santa Cruz Biotechnology Inc. (supplied by Autogen Bioclear,
Wilts, UK). Recombinant human VEGF165 was obtained from Gen-
zyme Diagnostics (Kent, UK). All other reagents were obtained from
Sigma Chemical Company (Dorset, UK).
2.2. Cell culture
Bovine aortic endothelial cells (a kind gift from Dr M. Boarder,
University of Leicester) were maintained in DMEM containing 10%
foetal calf serum, 100 Wg/ml streptomycin and 100 U/ml penicillin
under 5% CO2/95% air in a humidi¢ed incubator at 37‡C. Before
challenge with agonists con£uent monolayers were washed three times
with phosphate-bu¡ered saline (PBS: 80 mM Na2HPO4, 20 mM
NaH2PO4, 100 mM NaCl, pH 7.5) and incubated for 24 h in
DMEM containing 10% foetal calf serum.
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2.3. Hypoxia
For experiments under low oxygen conditions, medium was pre-
gassed and £asks were £ushed with 2% oxygen, 5% CO2, the balance
made up with N2 (BOC Ltd, London, UK). Oxygen concentration
was measured using an electronic oxygen meter (Model 9071, Jenway
Ltd, Essex, UK) as per the manufacturer’s instructions. Flasks were
sealed and oxygen concentration monitored periodically. Where the
e¡ects of conditioned medium was tested, cells were made hypoxic or
maintained under normoxic conditions as above for a period of 18 h.
Media from £asks were collected, centrifuged at 1000Ug for 10 min
and passed through a 0.2 Wm ¢lter. After gassing to restore normoxia
the conditioned medium was added to fresh cells that had been
washed in PBS as above.
2.4. Assessment of tie-1 protein expression
Following exposure to control or experimental conditions cells were
washed twice with PBS and lysed by addition of 0.75% (w/v) sodium
dodecyl sulphate (SDS). Lysates and cell debris were scraped from
£asks and sonicated and an aliquot removed for determination of
protein content, using the Micro BCA protein assay (Pierce and
Warriner (UK), Cheshire, UK). The remainder was diluted with sam-
ple bu¡er containing 100 mM dithiothreitol and heated to 105‡C for
5 min. Equal amounts of protein were loaded onto each lane of a 10%
polyacrylamide gel and subjected to electrophoresis in the presence of
sodium dodecyl sulphate. Following electrophoresis, proteins were
transferred to nitrocellulose membranes and probed with an a⁄nity-
puri¢ed antibody to tie-1. Immunoreactive bands were detected with a
peroxidase-conjugated secondary antibody and the ECL chemilumi-
nescent detection system (Amersham International Plc, Bucks, UK).
Bands on ¢lms were quantitated by scanning with an LKB Ultrascan
densitometer.
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Fig. 1. Time course of the e¡ect of hypoxia on expression of tie-1 protein in endothelial cells. Con£uent monolayers of endothelial cells were
cultured under hypoxic (2% O2) conditions for the times indicated followed by cell lysis. Equal amounts of cellular protein were resolved by
SDS-PAGE (10%) and tie-1 protein determined by Western blotting (A). Similar results were obtained in four independent experiments. The
positions of molecular mass markers are indicated in kDa. Densitometric scanning of blots was used to determine the level of tie-1 protein in
cells treated with hypoxia relative to control cells (B).
Fig. 2. Time course of the e¡ect of VEGF on expression of tie-1 protein in endothelial cells. Con£uent monolayers of cells were cultured under
normoxic (21% O2) conditions in the presence of 100 ng/ml VEGF for the times indicated followed by cell lysis. Equal amounts of cellular pro-
tein were resolved by SDS-PAGE (10%) and tie-1 protein determined by Western blotting (A). Similar results were obtained in four independ-
ent experiments. The positions of molecular mass markers are indicated in kDa. Densitometric scanning of blots was used to determine the lev-
el of tie-1 protein in cells treated with VEGF relative to control cells (B).
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3. Results
Endothelial cells were maintained under normoxic (21% O2)
or hypoxic (2% O2) conditions for various times then lysed
and expression of tie-1 protein determined by immunoblot-
ting. Aortic endothelial cells express tie-1 and under the con-
ditions of this study the receptor migrates in SDS-PAGE as a
doublet of approximately 130 and 125 kDa, the larger form
predominating (Fig. 1A, Fig. 2A). Expression of tie-1 protein
is increased in response to hypoxia in a time-dependent man-
ner (Fig. 1A,B), with the increase apparent as early as 1 h
after initiation of hypoxia. In addition to hypoxia newly form-
ing vessels are exposed to the angiogenic growth factor
VEGF. We reasoned, therefore, that VEGF may also modu-
late tie-1. To test this endothelial cells were challenged with
recombinant VEGF and tie-1 protein determined by immuno-
blotting. VEGF increased expression of tie-1 protein in a
time-dependent manner (Fig. 2A,B), again with increases
being observed 1 h after addition of the growth factor. In a
number of experiments hypoxia induced a 2.9-fold increase
(P6 0.01) and VEGF a 3-fold increase (P6 0.05) in tie-1
protein expression (Fig. 3). When hypoxia and VEGF were
present together, tie-1 increased to 2.4-fold of control cells
(P6 0.02), the e¡ects of the two stimuli were not additive.
Hypoxia has been shown to stimulate expression of VEGF
in human umbilical vein and human dermal microvascular
endothelial cells [15]. It is possible, therefore, that the e¡ects
of hypoxia on tie-1 could be mediated by induction of VEGF,
or indeed another autocrine factor. Consistent with this is the
failure of the combination of VEGF and hypoxia to induce
tie-1 beyond the level seen with each stimulus alone. To ex-
amine this possibility medium conditioned by endothelial cells
maintained under hypoxic conditions was collected and added
to fresh cells. Tie-1 expression was not increased by treating
cells with medium conditioned by hypoxic endothelial cells
indicating that the e¡ects of hypoxia on tie-1 are not mediated
by a secreted autocrine factor (Fig. 4).
Hypoxic induction of another angiogenic receptor tyrosine
kinase, VEGFR-2, in endothelial cells does not require in-
creased transcription [16]. This has led to the suggestion
that regulation of receptor tyrosine kinases by hypoxia may
be exerted at the post-transcriptional level [16]. We were in-
terested, therefore, to determine whether the e¡ects of hypoxia
or VEGF on tie-1 involved a transcriptional component. Ac-
tinomycin D at a concentration of 20 ng/ml, or control ve-
hicle, was added to cells 30 min before activation and cells
were challenged with hypoxia and VEGF as before. Tie-1
protein was not increased by either hypoxia or VEGF in cells
treated with actinomycin D, whereas both stimuli increased
tie-1 in control treated cells (Fig. 5).
4. Discussion
The present study is the ¢rst to identify factors that control
tie-1 protein expression in vascular endothelial cells. These
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Fig. 3. The e¡ect of hypoxia and VEGF on tie-1 protein expression
in endothelial cells. Con£uent endothelial cells were incubated under
hypoxic (2% O2) or normoxic (21% O2) conditions alone or in the
presence of 100 ng/ml VEGF for 16 h as indicated. Cells were lysed
and equal amounts of cellular protein were resolved by SDS-PAGE
(10%) and tie-1 protein determined by Western blotting. Levels of
tie-1 protein relative to control were determined by densitometric
scanning of blots. Results are presented for four independent experi-
ments as mean+SEM. *P6 0.05.
Fig. 4. E¡ect of medium conditioned by hypoxic endothelial cells
on tie-1. Medium was conditioned by cells incubated under nor-
moxic (21% O2) or hypoxic (2% O2) conditions for 16 h. Medium
was removed, cleared, ¢ltered and made normoxic before addition
to fresh endothelial cells. Cells were treated for 7 h with medium
conditioned by normoxic (Cm) or hypoxic (Hm) cells. After treat-
ment cells were washed, lysed and tie-1 protein measured by West-
ern blotting. Tie-1 expression in the normoxic (C) and hypoxic (H)
cells used for conditioning media is also presented.
Fig. 5. E¡ect of actinomycin D on hypoxia- and VEGF-induced tie-
1 in endothelial cells. Con£uent monolayers of endothelial cells were
treated for 15 min with 20 ng/ml actinomycin D or control vehicle.
Cells were then maintained with actinomycin D or control vehicle
under normoxic (21% O2) or hypoxic (2% O2) conditions or treated
with 100 ng/ml VEGF, as indicated. Cells were washed, lysed and
tie-1 protein analysed by Western blotting.
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factors, hypoxia and VEGF, are closely associated with active
angiogenic sites in pathological conditions and developmental
vascularisation [14] and are therefore likely to mediate the
increased expression of tie-1 seen in these situations. Induc-
tion of tie-1 protein by either stimulus is time-dependent with
levels reaching up to 3-fold those of control cells. Hypoxia has
been shown to upregulate expression of another angiogenic
receptor tyrosine kinase in vitro, VEGFR-2, either due to
the direct e¡ects of hypoxia on endothelial cells [16,17] or
via a factor released from smooth muscle cells in response
to decreased oxygen tension [18]. Where hypoxia acts directly,
VEGFR-2 levels are increased to approximately 1.5-fold of
control cells [17]. Previous observations that hypoxia can in-
crease VEGF expression in endothelial cells [15], and the ef-
fects of VEGF seen in the present study, suggested that hy-
poxia could act to increase tie-1 by increasing production of
VEGF or another autocrine factor. However, the inability of
conditioned medium from hypoxic cells to increase tie-1 ex-
pression argues against involvement of a secreted intermediate
factor. Our observation that actinomycin D inhibits induction
of tie-1 protein by hypoxia and VEGF is consistent with the
idea that these stimuli a¡ect expression of this receptor tyro-
sine kinase at the level of transcription. This is in contrast to
the direct e¡ects of hypoxia on VEGFR-2 which appear to be
independent of transcription [16].
VEGF is a direct potent stimulator of endothelial cell pro-
liferation and migration in vitro [19^23], and is angiogenic in
vivo [19,24]. In addition it induces expression of proteases
which have a role in degradation of the vascular basement
membrane early in angiogenesis [25]. Expression of VEGF is
increased under conditions of hypoxia in vivo, including
wound healing [26], in the ischaemic myocardium [27] and
tumour growth [28,29]. Exposure of several cell types to low
oxygen tension in vitro, including vascular smooth muscle and
endothelial cells, induces VEGF expression [15,30]. Con-
versely, in the retina, high oxygen tension inhibits VEGF ex-
pression leading to apoptosis of retinal endothelial cells and
vessel regression [31]. Together these observations support a
model whereby vessel growth is matched to the oxygen re-
quirements of the tissue. The ability of hypoxia and VEGF
to modulate tie-1 re¢nes this model further to include a mech-
anism whereby new vessels are primed to respond to tie
ligands which may have a role in later stages of the angiogenic
programme to promote vessel integrity.
The e¡ects of hypoxia on several genes, including VEGF,
are mediated largely by hypoxia-inducible factor-1 (HIF-1), or
a related HIF [32]. Examination of the 5P £anking region of
the tie-1 gene [33] did not reveal any cis-acting elements
closely similar to those known to interact with HIF-1 in
VEGF or other hypoxia-sensitive genes. It is possible that
consensus HIF binding sites exist further upstream than the
current published tie-1 5P untranslated region. Alternatively,
hypoxia could be acting indirectly or by an HIF or HIF-like
transcription factor interacting with hypoxia-responsive ele-
ments distinct from those known to bind HIF-1. In this re-
gard, it is noteworthy that several groups have recently re-
ported cloning HIF-1-related sequences that are
preferentially expressed in endothelial cells and the developing
vascular system, and that mediate hypoxia-induced transcrip-
tional activation [34^36]. These sequences have been desig-
nated endothelial PAS-1 (EPAS-1), HIF1K-like factor (HLF)
and HIF-related factor (HRF), and appear to be present at
much higher levels than HIF-1K in the vasculature [34^36].
The close similarity between sequences suggest they may en-
code the same or very closely related factors. Over-expression
of EPAS-1 induces expression of a reporter construct contain-
ing 10.3 kbp of regulatory sequence from the tie-2 gene [36].
Importantly this reporter gene was not stimulated by HIF-1K,
suggesting that EPAS-1 could interact with speci¢c response
elements not recognised by HIF-1K. It would be of consider-
able interest to determine whether the e¡ects of hypoxia on
tie-1 are mediated by EPAS-1.
In conclusion, this study demonstrates that hypoxia and
VEGF increase expression of tie-1 protein in vascular endo-
thelial cells. These observations provide a potential mecha-
nism for the increased expression of this receptor seen in sit-
uations of active angiogenesis, including wound healing,
tumour growth and development. The ability of VEGF to
modulate tie-1 demonstrates this growth factor has a function
in co-ordinating the angiogenic programme in endothelial
cells, being able to initiate early stages in vessel growth as
well as upregulate factors involved in the later stages of vessel
maturation.
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